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ABSTRACT 
 
Background/Aims 
 
Mycophenolate mofetil (MMF) is a powerful immunosuppressant that inhibits the 
proliferation of lymphocytes by blocking the enzyme inosine monophosphate 
dehydrogenase. MMF prevents acute graft rejection in organ transplants. The aim of 
this investigation is to study whether MMF has any influence on apoptosis and 
proliferation rates of cells other than lymphocytes.  
 
Methods 
 
We conducted a retrospective study of renal allograft biopsies taken during the 1st week 
after transplantation in 25 patients receiving triple therapy with prednisone, ciclosporin 
and azathioprine 75 mg/day and in 25 patients treated with MMF at a dose of 2 g/day 
instead of azathioprine, in order to investigate the differences in the proliferation and 
apoptosis rates of the glomerular, tubular, interstitial and endothelial cells of the kidney. 
Twelve normal kidneys were used as controls. Conventional histopathological 
techniques were applied as usual for pathological diagnosis. Proliferative activity was 
assessed by use of MIB-1 antibody. Sections of formalin-fixed, paraffin-embedded 
tissue blocks were stained for the presence of apoptotic cells by TUNEL assay. 
Evaluation of proliferative or apoptotic rates was made by counting the number of 
positive cells in 10 glomeruli and in 10 transversely cut tubuli in each biopsy. The 
positive cells in the interstitium were counted in ten high-power fields. Positive cells in 
the endothelium were scored semiquantitatively from 0 to 3: 0 = none, 1 = isolated cells, 
2 = small groups of cells, 3 = most endothelial cells. Mann-Whitney U and chi-square 
tests were used for intergroup comparisons.  
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Results 
 
All biopsies were normal or had borderline (Banff classification) acute rejection. MIB-1 
rates were similar in both groups, without statistical differences (p > 0.05) between 
them. Significantly lower apoptotic rates were found in the group treated with MMF in 
tubular epithelium (23.41 ± 8.86 vs. 57.4 ± 13.42; p = 0.021), in glomerular (1.25 ± 0.78 
vs. 5.3 ± 1.66; p = 0.027), and interstitial cells (1.58 ± 0.6 vs. 5.8 ± 1.54; p = 0.043). 
Apoptosis in endothelial cells (p > 0.05) was similar in both groups.  
 
Conclusion 
 
We conclude that treatment with MMF of kidney transplant patients does not affect the 
proliferative rate of cells of the allograft, but decreases the number of apoptotic cells in 
tubular epithelium. 
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INTRODUCTION 
 
Mycophenolate mofetil (MMF) is a semisynthetic derivative of the antimetabolite 
mycophenolic acid which inhibits the enzyme inosine monophosphate dehydrogenase 
(IMPDH). This enzyme catalizes the conversion of inosine to guanine monophosphate 
which is required for purine synthesis during mitoses. In solid-organ transplantations, 
MMF prevents acute graft rejection, inhibiting T and B cell proliferation [I] which 
induces death of tubular epithelial cells by apoptosis which is followed by epithelial 
regeneration [2]. 
 
The efficacy of MMF in preventing acute rejection, through inhibition of IMPDH, must 
have some influence over other proliferating cells. There is an initial loss of tubular 
epithelial cells by apoptosis after transplantation that sometimes is important enough to 
cause true tubular necrosis and renal insufficiency. Epithelial proliferation occurs in the 
early phase after tubular necrosis, and excess hyperplastic epithelial cells regress during 
the repair process by cell desquamation and apoptosis, both of which are essential for 
the recovery of the original tubular structure [3-5]. The fact that immunosuppression 
with MMF results in a markedly reduced number and grade of acute rejection episodes 
[1], suggests a protective role of this drug over all renal cells. 
 
The aim of this work is to study the influence of MMF treatment on both apoptosis and 
proliferation of different cell types in renal allografts during the 1st week after 
transplantation, in the absence of acute rejection. 
 
 
 
MATERIALS AND METHODS 
 
Biopsy Specimens 
 
A total of 75 renal biopsy specimens were selected on the basis of clinical history. 
Cases were classified as follows: 
 
Group A comprised 25 specimens from normal kidneys collected at autopsy from 
patients who died less than 6 h before of causes unrelated to renal pathology. 
 
Group B included 25 biopsy specimens taken between days 4 and 7 after renal 
transplantation. The patients received triple therapy with prednisone, ciclosporin and 
azathioprine at a dose of 75 mg/day. The levels of ciclosporin were maintained at 250-
350 ng/ml at the time of biopsy. Renal function at biopsy was normal in all cases. 
Biopsies of groups B and C (see below) were taken following a protocol which included 
a biopsy during the lst week after transplantation. 
 
Group C consisted of 25 specimens taken during the lst week after renal transplantation. 
The patients received triple therapy with prednisone, ciclosporin and MMF at a dose of 
2 g/day, following the criteria of Ducloux et al. [1, 6]. The levels of ciclosporin were 
maintained at 250-350 ng/ml at the time of biopsy. Renal function at biopsy was normal 
in all cases. 
  
 
The age of the patients was similar in all groups (mean 46, range 22-61 years). All 
patients were transplanted in our institution with similar technique and time of ischemia. 
All biopsies of the groups B and C were normal or had borderline (Banff classification) 
acute rejection. Signs of tubular necrosis were absent in all specimens. 
 
Sections from formalin-fixed, paraffin-embedded tissue blocks were stained with 
conventional histopathological techniques including hematoxylin-eosin, periodic acid-
Schiff, Masson's trichrome, methyl green-pyronin and silver methenamine. 
 
 
Inmunostaining 
 
Proliferative activity was assessed by immunoreactivity to ki67 antibody (done MIB-1; 
Immunotech, Marseille, France), using the standard avidin-biotin-peroxidase complex 
(DAKO) method. The ki67 is a carefully selected synthetic immunogen which 
ascertains a very high specificity: it labels proliferating cells in man and many other 
mammalian species [7]. Simultaneous staining was performed for MIB-1 and negative 
controls which included substitution of the monoclonal primary antibody for mouse 
myeloma proteins of the same subclass and concentration as the monoclonal antibody. 
 
Sections were deparaffinized in xylene, rehydrated through graded alcohols and 
incubated 2 x 5 min in citrate buffer (pH 6.0) in a household microwave oven at 800 W. 
After microwave exposure, the slides were allowed to cool down to room temperature. 
The slides were briefly washed with Tris-buffered saline (pH = 7.4) and incubated for 
20 mM with 3% H2O2 in water to block endogenous peroxidase activity. MIB-1 
antibody was used at 1:100 dilution and incubated for 30 min at room temperature. 
Biotinylated antimouse/rabbit antibody (DAKO) at a dilution 1:100 was used as the 
linking molecule. After washing, avidin-biotin-peroxidase complex was applied, and 
aminoethyl carbazole was used for visualization. 
 
 
In situ Apoptosis Assay 
 
Sections from selected formalin-fixed, paraffin-embedded tissue blocks were placed on 
coated slides. This study was conducted to examine the occurrence of apoptotic cell 
death in formalin-fixed, paraffin-embedded biopsy specimens from allografted kidneys 
by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin 
nick end labeling (TUNEL) method, using digoxigenin-conjugated deoxyuridine 
triphosphate and anti-digoxigenin antibody labelled with peroxidase. Briefly, tissue 
sections were dewaxed and rehydrated routinely. After rehydration, the slides were 
incubated with proteinase K (20 mg/ml) at room temperature for 15 min. Endogenous 
peroxidase was inactivated by 3% hydrogen peroxide. Tissue sections were stained with 
an ApopTag system (Oncor, Gaithersburg, Md., USA) that identifies cells with 
internucleosomal fragmentation of DNA (apoptosis). The procedure was performed 
according to the manufacturer's instructions. The reaction was terminated after 60 min 
by transfer of the slides to a Coplin jar containing prewarmed working strength stop-
wash buffer and incubated for 30 min at 37 ° C. The sections were then covered with 55 
ml of anti- digoxigenin-peroxidase and incubated for 30 min at room temperature and 
stained with diaminobenzidine to detect the biotin-labelled nuclei. 
The method is based on the preferential binding of terminal deoxynucleotidyl 
transferase to the 3'-hydroxyl ends of DNA. Briefly, residues of digoxigenin 
deoxyuridine triphosphate were catalytically added to the ends of DNA fragmenta with 
the enzyme terminal deoxynucleotidyl transferase. 
 
Deionized water was used instead of terminal deoxynucleotidyl transferase for negative 
controls. Positive controls for immunohistochemistry and TUNEL assay consisted of 
inflamed human tonsils. Cells were considered to be apoptotic when a strong brown 
nuclear reactivity was observed. 
 
 
Evaluation 
 
A blind study was made of all slides by two different observers, counting the median 
value for each appraisal. Evaluation of proliferative or apoptotic rates were made 
counting the number of positive cells in 10 glomeruli and in 10 transversely cut tubuli in 
each biopsy specimen. The positive cells in the interstitium were counted in ten high-
power fields. Positive cells in the endothelium were scored semiquantitatively from O to 
3: 0 = none, 1 = isolated cells, 2 = small groups of cells, 3 = most endothelial cells. 
 
 
Statistics 
 
Data are expressed as mean ± SEM. In order to study the differences in the proliferation 
and apoptosis rates of the glomerular, tubular, interstitial and endothelial cells of the 
kidney, data were analyzed using the chi- squared test. Normally distributed, multiple-
sample, continuous data were analyzed with analysis of variance, while those with 
nonnormal distribution were analyzed using the Mann-Whitney U test. p < 0.05 was 
considered significant. 
 
 
 
RESULTS 
 
Microscopically all biopsies were normal or showed small groups of lymphocytes 
without tubulitis. Isolated mitoses or eosinophilic bodies were occasionally found in 
tubuli. 
 
MIB-1 rates in glomeruli, tubular epithelial cells, interstitial cells and endothelium were 
similar in groups B and C, without statistical differences (p > 0.05; table 1, fig. 1). MIB-
1 antibody was only positive in the nuclei of isolated tubular or glomerular cells and in 
lymphocytic infiltrate. 
 
TUNEL positivity was occasionally observed in groups B and C in all cellular types 
(glomerular, tubular, interstitial and endothelial cells). In general, significantly lower 
apoptotic rates were found in the group treated with MMF (group C) as compared with 
group B in glomerular (1.25 ± 0.78 vs. 5.3 ± 1.66; p = 0.027), tubular (23.41 ± 8.86 vs. 
57.4 ± 13.42; p = 0.021) and interstitial (1.58 ± 0.6 vs. 5.8 ± 1.54; p = 0.043) cells (table 
2; fig. 2). In the MMF group (group C), 91.66% of the cells studied had grade 0-1 
endothelial apoptosis, whereas only 40% of the cells in group B had grade 0-1 
endothelial apoptosis (p = 0.03). Isolated apoptotic cells were found in tubuli of normal 
kidneys (group A). The distribution of apoptotic cells within the graft was homogeneous 
without preference for any localization. 
 
 
 
DISCUSSION 
 
Over the past decades, treatment with ciclosporin, azathioprine and prednisone has been 
widely considered to be the most effective combination for prophylactic 
immunosuppression following cadaveric renal transplantation [6]. The use of MMF 
instead of azathioprine reduces the incidence and severity of biopsy-proven acute 
rejection [1, 6], and decreases the need for multiple courses of steroids and the use of 
antilymphocyte preparations for treatment of rejection [8, 9]. MMF does not change the 
incidence of death as compared with the other treatment group, but prolongs allograft 
survival in many laboratory animals [10, 11]. In this paper we have tried to demonstrate 
the role of MMF in the protection of tubular epithelium during the 1st week after 
transplantation, studying selected renal biopsy specimens without acute rejection or 
tubular necrosis. 
 
MMF is rapidly converted to mycophenolic acid, a potent inhibitor of IMPDH which 
lastly reduces guanine nucleotide pools. It selectively inhibits DNA synthesis and 
guanosine triphosphate dependent metabolic events [12], which are essential for mitoses 
in many cell types, including T and B lymphocytes [1]. MMF may exhibit a marked 
antiproliferative effect without toxicity in mono-nuclear cultures through inhibition of 
the production of cytokines [13] or block the ability of cytokine receptors to activate 
cell cycling, interfering with clonal expression [14]. MMF inhibits proliferation of cells 
other than lymphocytes, such as smooth muscle cells in rat aortic allografts [15], but 
this effect is not universal, since we have demonstrated that it does not inhibit the 
proliferation of tubular epithelium: it allows the easy compensation of cell loss due to 
ischemia during the first days after transplantation [16]. 
 
Apoptotic cell death can be examined using several techniques, such as 3' end labeling 
with terminal transferase, gel fractionation, Southern blotting and other 
immunohistological techniques. It is generally accepted that apoptosis and necrosis 
cannot be differentiated using a single technique [17], but if there are no other reasons 
for necrosis, the TUNEL technique has been considered sufficient to demonstrate 
evidence of increased apoptotic cell death [4, 17]. The main problem of the TUNEL 
technique is to distinguish between leukocytes and epithelial apoptotic cells when there 
is a well-established acute rejection episode. 
 
Poor initial function is common in cadaveric renal transplantation and is usually 
attributed to tubular epithelial apoptosis brought about by ischemia during 
harvesting/implantation [3, 4, 18]. Apoptosis is also increased in renal tubular epithelial 
cells of patients having chronic [17] and acute [19] renal allograft rejection. The 
induction of apoptosis may be due to an imbalance between cytokine secretion and 
cytokine deprivation [20, 21] caused by MMF treatment. Nevertheless, caution must be 
exercised not to simply attribute the observed effects to the presence of MMF in the 
therapeutic regimen, but rather to the replacement of azathioprine by MMF or the 
interactions of the different drugs used in the triple-treatment regimes. It remains to be 
formally demonstrated that the addition of MMF to a dual-drug regimen would give the 
same results. T cell (and possibly macrophage) mediated cytotoxicity plays an 
important role in acute renal allograft rejection, particularly in the case of tubular injury, 
and furthermore suggests that apoptosis may be a mechanism not only for graft cell 
destruction, but also for elimination of activated T cells in the infiltrate [22]. 
 
MMF reduces the incidence of biopsy-proven acute rejection, the incidence of 
histologically severe rejection and the graft loss [1]. The maintenance of the capacity of 
proliferation of renal cells and the decrease of apoptosis rate have a worthy consequence 
to the patient. It is possible that MMF has a protective effect against apoptosis, which is 
a very important mechanism of cell loss in chronic rejection [23]. This would explain 
the prolonged allograft survival in many laboratory animals [8, 9]. Fas is expressed by 
tubular epithelium, but Fas-mediated apoptosis does not play a role in the induction of 
apoptosis during renal transplant rejection [24-26]; however, this mechanism may be 
very important in ischemia. 
 
These data suggest that immunosuppression with MMF represents a more effective 
approach in renal transplantation, because it provides a protection against the loss of 
tubular epithelial cells by apoptosis. This is the first report which demonstrates a 
probable protective effect of MMF against apoptosis during the 1st week after 
transplantation, without changing the proliferation rate of other renal cell types. Further 
studies would be necessary to see whether MMF keeps this protective effect during 
long-term treatment. 
  
 
REFERENCES 
 
1. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A 
blinded, randomized clinical trial of mycophenolate mofetil for the prevention of 
acute rejection in cadaveric renal transplantation. Transplantation 1996:61:1029-
1037. 
2. Robertson H, Wheeler J, Thompson V, Johnson JS, Kirby JA, Morley AR: In situ 
lymphoproliferation in renal transplant biopsies. Histochemistry 1995;104:331-334. 
3. Shimizu A, Yamanaka N: Apoptosis and cell desquamation in repair process of 
ischemic tubular necrosis. Virchows Arch B Cell Pathol Incl Mol Pathol 
1993;64:171-180. 
4. Matsuno T, Sasaki H, Ishido N, Matsuda H, Sadamori H, et al: Apoptosis in human 
kidney allografts. Transplant Proc 1996;28:12261227. 
5. Lieberthal W, Menza SA, Levine JS: Graded ATP depletion can cause necrosis or 
apoptosis of cultured mouse proximal tubular cells. Am J Physiol 1998;274:F315-
F327. 
6. Ducloux D, Fournier V, Bresson-Yautrin C, Rebibou JM, Billerey C, Saint-Hillier 
Y, Chalopin JM: Mycophenolate mofetil in renal transplant recipients with 
cyclosporine-associated nephrotoxicity: A preliminary, report. Transplantation 
1998;65:1504-1506. 
7. Rose DSC, Maddox PH, Brown DC: Which proliferation markers for routine 
immunohistology? A comparison of five antibodies. J Clin Pathol 1994;47:1010-
1014. 
8. Gonwa TA: Mycophenolate mofetil for maintenance therapy in kidney 
transplantation. Clin Transplant 1996;10:128-130. 
9. Danovitch GM: Mycophenolate mofetil in renal transplantation: Results from US 
randomized trials. Kidney Int 1995;52(suppl):93-96. 
10. Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC: Mycophenolic acid 
morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and 
halts heart allograft rejection by selective inhibition of T- and B-cell purine 
synthesis. Transplant Proc 1990;22: 1659-1662. 
11. Bechstein WO, Schilling M, Steele DM, Hullet DA, Sollinger HW: RS-
61443/cyclosporine combination therapy prolongs canine liver allograft survival. 
Transplant Proc 1993;25:702703. 
12. Ransom JT: Mechanism of action of mycophenolate mofetil. Ther Drug Monit 
1995;17:681-684. 
13. Nagy SE, Andersson JP, Andersson UG: Effect of mycophenolate mofetil (RS-
61443) on cytokine production: Inhibition of superantigen-induced cytokines. 
Immunopharmacology 1993;26:11-20. 
14. Halloran PF: Molecular mechanisms of new immunosuppressants. Clin Transpl 
1996;10: 118-123. 
15. Raisanen Sokolowski A, Vuoristo P, Myllarniemi M, Yilmaz S, Kallio E, Hayry P: 
Mycophenolate mofetil (MMF, RS 61443) inhibits inflammation and smooth 
muscle cell proliferation in rat aortic allografts. Transpl Immunol 1995;3:342-351. 
16. Shoskes DA, Halloran PF: Delayed graft function in renal transplantation: Etiology, 
management and long-term significance. J Urol 1996; 155:1831-1840. 
17. Laine J, Etelamaki P, Holmberg C, Dunkel L: Apoptotic cell death in human 
chronic renal allograft rejection. Transplantation 1997;63: 101-105. 
18. Parmar MS, Kjellstrand CM, Solez K, Halloran PF: Glomemlar endothelial cell 
detachment in paired cadaver kidney transplants: Evidence that some cadaver 
donors have preexisting endothelial injury. Clin Transplant 1994;8:120-127. 
19. Ito H, Kasagi N, Shomori K, Osaki M, Adachi H: Apoptosis in the human 
allografted kidney: Analysis by terminal deoxynucleotidyl transferase-mediated 
DUTP-biotin nick end labeling. Transplantation 1995;60:794-798. 
20. Lin Y, Benchimol S: Cytokines inhibit p53- mediated apoptosis but not p53-
mediated G1 arrest. Mol Cell Biol 1995;15:6045-6054. 
21. Oyaizu N, McCloskey TW, Than S, Pahwa S: Inhibition of CD4 cross-linking-
induced lymphocyte apoptosis by vesnarinone as a novel immunomodulating agent: 
Vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion. 
Blood 1996;87:2361. 
22. Meehan SM, McCluskey RT, Pascual M, Preffer FI, Anderson P, Schlossman SF, 
Colvin RB: Cytotoxicity and apoptosis in human renal allografts: Identification, 
distribution, and quantitation of cells with a cytotoxic granule protein GMP-17 
(TIA-1) and cells with fragmented nuclear DNA. Lab Invest 1997;76:639-649. 
23. Wang J, Nonomura N, Ichimaru N, et al: Expression of Fas and Fas ligand in renal 
grafts with acute and chronic rejection in the rat model. J Interferon Cytokine Res 
1997;17:369. 
24. Boonstra JG, van der Woude FJ, Wever PC, Laterveer JC, Daha MR, van Kooten 
CJ: Expression and function of Fas (CD95) on human renal tubular epithelial cells. J 
Am Soc Nephrol 1997;8:1517-1524. 
25. Swenson KM, Ke B, Wang T, Markowitz JS, Maggard MA, Spear GS, Imagawa 
DK, Goss JA, Busuttil RW, Seu P: Fas ligand gene transfer to renal allografts in 
rats: Effects on allograft survival. Transplantation 1998;65:155-160. 
26. Kato S, Akasaka Y, Kawamura S: Fas antigen expression and its relationship with 
apoptosis in transplanted kidney. Pathol Int 1997;47: 230-237. 
Table 1. Proliferation rates in glomeruli, tubular epithelial cells and 
interstitial cells (Mann-Whitney U test) 
 Group A Group C Group B p 
Glomeruli 0.01 ± 0.002 0.33 ± 0.18 1.3 ± 0.65 0.31 
Tubules 0.3 ± 0.1 6.33± 1.76 7.1 ± 2.02 0.71 
Interstitium 0 3.83 ± 1.35 2.1 ± 0.45 0.5 
 
 
 
 
 
Table 2. Apoptotic rates in glomeruli, tubular epithelial cells and 
interstitial cells (Mann-Whitney U test). 
 Group A Group C Group B p 
Glomeruli 0 1.25 ± 0.78 5.3 ± 1.66 0.027 
Tubules 0.1 ± 0.03 23.41 ± 8.86 57.4 ± 13.42 0.021 
Interstitium 0 1.58 ± 0.6 5.8 ± 1.54 0.043 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Immunohistochemical staining of renal biopsy specimens by MIB-1 antibody. 
A Treatment with MMF. x 85. B Immuno-suppression with azathioprine. x 170. The 
number of positive cells was similar in both groups. Light-green counterstain. 
 
 
 
 
 
Figure 2. In situ assay for apoptosis. A Numerous positive nuclei in a kidney biopsy 
specimen of a patient treated with azathioprine. Note the positivity in endothelial cells. 
x 170. B Isolated positive cells in a patient treated with MMF. x 85. Light-green 
counterstain. 
